Get the Stockscreener App
6.18
3.34%
0.20
After Hours:
6.18
Evolus Inc stock is traded at $6.18, with a volume of 650.24K.
It is up +3.34% in the last 24 hours and down -13.32% over the past month.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
See More
Previous Close:
$5.98
Open:
$6.05
24h Volume:
650.24K
Relative Volume:
0.79
Market Cap:
$406.98M
Revenue:
$301.79M
Net Income/Loss:
$-43.42M
P/E Ratio:
-9.217
EPS:
-0.6705
Net Cash Flow:
$-44.87M
1W Performance:
+11.45%
1M Performance:
-13.32%
6M Performance:
+24.85%
1Y Performance:
-35.15%
1-Day Range:
$6.05
$6.31
1-Week Range:
$5.47
$6.31
52-Week Range:
$3.86
$9.58
Evolus Inc Stock (EOLS) Company Profile
Name
Evolus Inc
Sector
Phone
(949) 284-4555
Address
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
6.18 | 393.81M | 301.79M | -43.42M | -44.87M | -0.6705 |
TAK
Takeda Pharmaceutical Co Adr
|
17.44 | 55.06B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.94 | 43.07B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.08 | 35.88B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.92 | 31.59B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
527.94 | 26.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Downgrade | Needham | Buy → Hold |
| Apr-17-25 | Initiated | BTIG Research | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-23-22 | Initiated | Needham | Buy |
| May-12-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| May-06-21 | Upgrade | Mizuho | Neutral → Buy |
| Apr-08-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-21 | Downgrade | Truist | Buy → Hold |
| Jul-07-20 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-20 | Resumed | Mizuho | Buy |
| Nov-26-19 | Initiated | SVB Leerink | Outperform |
| Sep-05-19 | Resumed | Mizuho | Buy |
| Jun-28-19 | Initiated | Wells Fargo | Market Perform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
View All
Evolus Inc Stock (EOLS) Latest News
Evolus Inc (EOLS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Evolus, Inc. Common Stock Revenue Breakdown – NASDAQ:EOLS - TradingView
Evolus Inc (EOLS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Evolus, Inc. (EOLS) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Evolus Inc (EOLS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Evolus, Inc. (EOLS) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Evolus Inc (EOLS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Evolus, Inc. (EOLS) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Press Release: Evolus to Report Second Quarter Financial Results on August 5, 2026 - Moomoo
Evolus to Report Second Quarter Financial Results on August 5, 2026 - Yahoo Finance
Evolus Inc. (EOLS) Slips 3.2% as Stock Approaches Key Support LevelCall Wall - dars.gov.et
Evolus, Inc. (EVL) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Evolus, Inc. (EVL) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Evolus, Inc. (EVL) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Evolus, Inc. (EVL) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Evolus, Inc. (EVL) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
(EOLS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Analysts Conflicted on These Healthcare Names: Irhythm Technologies (IRTC), Penumbra (PEN) and Evolus (EOLS) - The Globe and Mail
Evolus signs licensing deal for Profhilo skin injectable in US By Investing.com - Investing.com Nigeria
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Evolus Class Action Reminder - TMX Newsfile
Analysts’ Top Healthcare Picks: Evolus (EOLS), Annovis Bio (ANVS) - The Globe and Mail
One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics - Finansavisen
ETFs Investing in Evolus, Inc. Stocks - TradingView
Evolus Lands Licensing Rights for Profhilo - Orange County Business Journal
Evolus, IBSA Partner to Develop and Commercialize Skin Quality Filler in the US - The Dermatology Digest
Evolus Partners with IBSA to Launch Profhilo® Injectable for Skin Quality in the U.S., Expanding Aesthetic Portfolio - Minichart
Evolus signs licensing deal for Profhilo skin injectable in US - Investing.com
Evolus Partners With IBSA to Develop, Commercialize Profhilo in US - Moomoo
Evolus Secures Exclusive U.S. Profhilo License From IBSA; No Upfronts, 15-Year Term - TradingView
Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality - Yahoo! Finance Canada
Needham Maintains Evolus(EOLS.US) With Hold Rating - Moomoo
Evolus (EOLS) Slides 0.86% as Stock Hovers Near Support – Market Sentiment Weighs on Aesthetics PlayerBeta Neutral Pair - dars.gov.et
EOLSEvolus Inc Options - Finviz
Evolus (EOLS) price target decreased by 11.11% to 14.96 - MSN
Evolus Q1 2026 earnings preview - MSN
Price to sales forward of Evolus, Inc. Common Stock – NASDAQ:EOLS - TradingView
Enterprise value to EBITDA forward of Evolus, Inc. Common Stock – NASDAQ:EOLS - TradingView
Enterprise value to revenue forward of Evolus, Inc. Common Stock – NASDAQ:EOLS - TradingView
Evolus, Inc. Actuals & Estimates (NASDAQ:EOLS) - TradingView
EVL Forecast — Price Target — Prediction for 2027 - TradingView
EOLS Forecast — Price Target — Prediction for 2027 - TradingView
Evolus Inc. (EOLS) Q1 2026 Earnings: EPS Surpasses Estimates, Signaling Operational ImprovementsEarnings Decline Risk - dars.gov.et
EOLS News | EVOLUS INC (NASDAQ:EOLS) - ChartMill
Evolus Inc (EOLS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Evolus, Inc.(NasdaqGM: EOLS) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
Is Evolus (EOLS) Finally Turning the Corner on Profitability - Kavout | AI
Evolus Inc. Q1 2026 Earnings: EPS Surprises Sharply to the Upside as Investor Sentiment Stays MutedEarnings Momentum Score - dars.gov.et
EOLS Q1 2026 Earnings: EPS Beat Expectations Despite Narrow LossProfit Recovery Report - DonanımHaber
Evolus Inc (EOLS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Evolus Inc (EOLS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Evolus Inc Stock (EOLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.30%
2.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):